What Is FOXO4-DRI? Definition and What Research Reports
FOXO4-DRI is a laboratory-designed peptide built from a short stretch of the FOXO4 protein and synthesised in D-amino acids in reverse order. Researchers designed it to interfere with the binding between FOXO4 and the tumour suppressor p53 inside senescent cells. In the original 2017 mouse and cell work, the study reported p53 nuclear exclusion and apoptosis that was selective for senescent cells. It remains a research compound; published data are preclinical, and later studies reported that senescent-cell clearance is not uniformly beneficial.
Plain-language definition
FOXO4-DRI is a short, laboratory-made peptide modelled on a fragment of a human protein called FOXO4. The "DRI" stands for D-retro-inverso, a chemical design trick in which the peptide is built from mirror-image (D-) amino acids assembled in reverse sequence, so that the molecule presents a similar shape to the original but resists being chopped up by the body's protein-cutting enzymes. It is studied as a senolytic — a substance intended to selectively remove "senescent" cells, which are damaged cells that stop dividing but stay alive and secrete inflammatory signals. FOXO4-DRI is a research reagent used in cell culture and animal experiments; it is not an approved medicine and has no established human use. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question.
What FOXO4-DRI is in biochemical terms
FOXO4 is a forkhead box transcription factor. In senescent cells, FOXO4 is enriched and physically associates with p53, the tumour-suppressor protein that can trigger programmed cell death. The 2017 Cell paper that introduced the peptide described FOXO4 as sequestering active p53 in the nucleus, thereby blocking p53-driven apoptosis and helping senescent cells persist; researchers designed a FOXO4-derived peptide to perturb that interaction, and the study reported that it caused p53 nuclear exclusion and cell-intrinsic apoptosis in senescent cells (PMID 28340339).
The FOXO4–p53 interface
Biophysical work has since mapped this interaction in more detail. One study reported that FOXO4 engages the p53 transactivation domain (TAD) and C-terminal regulatory domain (CRD) and that this binding inhibited p53 association with DNA (PMID 35481640). A 2025 structural analysis characterised the interaction between the FOXO DNA-binding domain and the p53 TAD as conformationally plastic rather than a single fixed pose, which the authors framed as relevant to designing molecules that interrupt it (PMID 40425537).
Why "retro-inverso"?
Natural L-peptides are degraded quickly by proteases. Retro-inverso design is a standard medicinal-chemistry strategy intended to extend half-life while preserving the spatial arrangement of key side chains. The "DRI" label in FOXO4-DRI therefore describes a chemical format, not a separate biological target: the target remains the FOXO4–p53 interaction.
Where the term comes from
The term entered the literature with the 2017 Cell study, which reported that the FOXO4 peptide neutralised doxorubicin-induced chemotoxicity in mice and, in fast-ageing Xpd mutant mice and naturally aged mice, restored measures of fitness, fur density and renal function (PMID 28340339). That single paper is the origin of nearly all popular discussion of the compound, and most subsequent FOXO4-directed work cites it as the starting point.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow the term is used — and where it is misused
In the research literature, "FOXO4-DRI" refers narrowly to the FOXO4-derived retro-inverso peptide used as a tool to test the FOXO4–p53 hypothesis of senescent-cell survival. Outside the literature, several misuses are common:
- Treating it as an approved anti-ageing therapy. The published evidence base is preclinical — cultured cells and rodent models. No human efficacy or safety trial appears in the verified literature summarised here.
- Equating "senolytic" with "beneficial". A 2023 Circulation study reported that eliminating senescent cells promoted the development and progression of pulmonary hypertension in the models examined, a direct counterexample to the assumption that clearance is always favourable (PMID 36515093).
- Confusing the peptide with FOXO4 itself. FOXO4 is an endogenous transcription factor with roles in redox signalling, cell-cycle control and senescence; FOXO4-DRI is a synthetic molecule designed to interrupt one of its protein–protein interactions.
- Assuming one mechanism, one outcome. Senescent cells are heterogeneous. Research on aged cartilage described distinct senescence "endotypes" that were reflected in the blood metabolome, indicating that senescence is not a single uniform state (PMID 37962736).
Related terms
| Term | Relationship to FOXO4-DRI |
|---|---|
| FOXO4 | The endogenous forkhead transcription factor from which the peptide sequence was derived; reported to bind the p53 TAD and CRD (PMID 35481640). |
| p53 | The tumour suppressor whose nuclear retention by FOXO4 the peptide was designed to disrupt (PMID 28340339). |
| Senolytic | Class term for agents intended to remove senescent cells; FOXO4-DRI is the prototype peptide-based example. |
| Cellular senescence | The stable growth-arrest state targeted; reviewed in the context of the ageing and diseased kidney (PMID 29260442). |
| Mdm2 / ubiquitination | Regulatory layer above FOXO4; researchers reported that Mdm2 induced mono-ubiquitination of FOXO4 (PMID 18665269). |
| USP7, USP37 (deubiquitinases) | Enzymes studied in adjacent p53- and FOXO4-related pathways rather than as FOXO4-DRI targets (PMID 41980094). |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appWhat the published literature reports
The founding senolytic experiments
The originating study reported selective apoptosis of senescent cells via p53 nuclear exclusion, and described restoration of tissue homeostasis in chemotoxicity and ageing models in mice (PMID 28340339). No dosing details are summarised here beyond what that abstract scope describes.
Follow-on peptide chemistry
A 2025 Journal of Medicinal Chemistry paper described newly designed peptide inhibitors targeting FOXO4–p53 interactions and reported apoptosis that was specific to senescent cancer cells, indicating continued medicinal-chemistry interest in the same interface (PMID 40739602). Structural work on the plasticity of the FOXO DNA-binding domain–p53 TAD complex has been presented as a design foundation for such efforts (PMID 40425537).
Non-peptide ways of hitting FOXO4
Researchers have also pursued nucleic-acid approaches. A 2023 study reported that DNA nanoparticles targeting FOXO4 selectively eliminated cigarette smoke-induced senescent lung fibroblasts, showing that the FOXO4 node can be addressed by modalities other than a retro-inverso peptide (PMID 37881696).
Upstream control of FOXO4 stability
Two lines of work describe how FOXO4 levels are governed. An earlier study reported that Mdm2 induced mono-ubiquitination of FOXO4 (PMID 18665269), and a 2026 PNAS report described a CHK2–USP37 axis that stabilised FOXO4 to sustain senescence and evade apoptosis (PMID 41980094). Related deubiquitinase research on USP7 reported p53-dependent cancer-cell killing after selective inhibition (PMID 32210275) and downregulation of PD-L1 with increased sensitivity to T-cell killing in gastric cancer cells after USP7 abrogation (PMID 33777676); these concern the wider ubiquitin–p53 network rather than FOXO4-DRI itself.
Senolytic Safety Signals: What Studies Report
The verified literature contains no human safety dataset for FOXO4-DRI. The most directly cautionary published finding concerns the senolytic concept generally: the 2023 Circulation study reported that eliminating senescent cells promoted pulmonary hypertension development and progression, indicating that senescent cells can serve context-dependent roles (PMID 36515093). Reviews of senescence in the kidney similarly described senescence as both damaging and protective depending on tissue and timing (PMID 29260442).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeWhat the literature does not establish
- Human efficacy, tolerability or pharmacokinetics for FOXO4-DRI.
- Whether rodent findings on fitness, fur density and renal function (PMID 28340339) translate to people.
- Which senescent-cell populations should or should not be removed, given heterogeneous senescence endotypes (PMID 37962736) and the pulmonary hypertension signal (PMID 36515093).
As a glossary entry, the practical takeaway is definitional: FOXO4-DRI names a protease-resistant peptide designed to break a specific protein–protein interaction, studied in preclinical models, and surrounded by an active but unresolved research literature.
References
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (Cell, 2017)
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression (Circulation, 2023)
- DNA nanoparticles targeting FOXO4 selectively eliminate cigarette smoke-induced senescent lung fibroblasts (Nanoscale Advances, 2023)
- Structural plasticity of the FOXO-DBD:p53-TAD interaction (Nature Communications, 2025)
- Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis (Journal of Medicinal Chemistry, 2025)
- FOXO4 interacts with p53 TAD and CRD and inhibits its binding to DNA (Protein Science, 2022)
- Mdm2 induces mono-ubiquitination of FOXO4 (PLoS One, 2008)
- CHK2-USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis (PNAS, 2026)
- Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism (Scientific Reports, 2020)
- Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing (Acta Pharmaceutica Sinica B, 2021)
- Cellular senescence in the aging and diseased kidney (Journal of Cell Communication and Signaling, 2018)
- Identified senescence endotypes in aged cartilage are reflected in the blood metabolome (GeroScience, 2024)
Frequently asked questions
What does the "DRI" in FOXO4-DRI stand for?▾
DRI stands for D-retro-inverso, a peptide design in which D-amino acids are assembled in reverse sequence so the molecule resists protease degradation while presenting a similar side-chain arrangement. The label describes chemistry, not a different target: the peptide was designed against the FOXO4–p53 interaction described in the originating senescence study (PMID 28340339).
What mechanism did researchers propose for FOXO4-DRI?▾
The 2017 study reported that FOXO4 binds p53 in senescent cells and that a FOXO4-derived peptide perturbed that interaction, causing p53 nuclear exclusion and cell-intrinsic apoptosis selective for senescent cells (PMID 28340339). Later biophysical work reported that FOXO4 engages the p53 transactivation and C-terminal regulatory domains and inhibited p53 binding to DNA (PMID 35481640).
Is FOXO4-DRI an approved drug?▾
No. Within the literature summarised here, FOXO4-DRI appears only in preclinical cell and rodent research, not as an approved medicine. Reported outcomes such as restored fitness, fur density and renal function came from mouse models of chemotoxicity and ageing (PMID 28340339). No human efficacy or safety trial is included among these verified papers.
Do all studies suggest removing senescent cells is helpful?▾
No. A 2023 Circulation study reported that eliminating senescent cells promoted pulmonary hypertension development and progression in the models examined (PMID 36515093). Reviews of kidney senescence described context-dependent roles for senescent cells (PMID 29260442), and cartilage research described distinct senescence endotypes reflected in the blood metabolome (PMID 37962736).
Are there newer molecules aimed at the same target?▾
Yes. A 2025 medicinal-chemistry paper described peptide inhibitors of FOXO4–p53 interactions that researchers reported induced apoptosis specific to senescent cancer cells (PMID 40739602). Separately, a 2023 study reported that DNA nanoparticles targeting FOXO4 selectively eliminated cigarette smoke-induced senescent lung fibroblasts (PMID 37881696).
How is FOXO4 itself regulated inside cells?▾
Regulation occurs partly through the ubiquitin system. One study reported that Mdm2 induced mono-ubiquitination of FOXO4 (PMID 18665269), and a 2026 report described a CHK2–USP37 axis that stabilised FOXO4 to sustain senescence and evade apoptosis (PMID 41980094). These pathways concern endogenous FOXO4 biology rather than the synthetic peptide.
What is the difference between FOXO4 and FOXO4-DRI?▾
FOXO4 is a naturally occurring forkhead transcription factor present in human cells and enriched in senescent cells. FOXO4-DRI is a synthetic peptide modelled on part of that protein and built in retro-inverso form to interrupt FOXO4's association with p53, as described in the originating senolytic study (PMID 28340339) and follow-on structural work (PMID 40425537).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.